Serum interleukin-22 and vascular endothelial growth factor serve as sensitive biomarkers but not as predictors of therapeutic response to biologics in patients with psoriasis

Journal of Dermatology

Volumn 40, Issue 10, 2013, Pages 805-812

  Shimauchi, Takatoshi ^a,c   Hirakawa, Satoshi ^a   Suzuki, Takahiro ^a   Yasuma, Ayako ^a   Majima, Yuta ^b   Tatsuno, Kazuki ^a   Yagi, Hiroaki ^b   Ito, Taisuke ^a   Tokura, Yoshiki ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHIZUOKA GENERAL HOSPITAL   (Japan)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

biologics; biomarkers; interleukin 22; psoriasis; vascular endothelial growth factor

Indexed keywords

ADALIMUMAB; INFLIXIMAB; INTERLEUKIN 22; USTEKINUMAB; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FOLLOW UP; HUMAN; HUMAN TISSUE; PROTEIN BLOOD LEVEL; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PUSTULAR PSORIASIS; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE;

BIOLOGICS; BIOMARKERS; INTERLEUKIN-22; PSORIASIS; VASCULAR ENDOTHELIAL GROWTH FACTOR;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL MARKERS; FEMALE; HUMANS; INTERLEUKINS; MALE; MIDDLE AGED; PSORIASIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TH17 CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84885180849     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/1346-8138.12248     Document Type: Article

References (33)

1. Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, et al,. Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol 2009; 129: 79-88.
2. Koga C, Kabashima K, Shiraishi N, Kobayashi M, Tokura Y,. Possible pathogenic role of Th17 cells for atopic dermatitis. J Invest Dermatol 2008; 128: 2625-2630.
3. Di Cesare A, Di Meglio P, Nestle FO,. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 2009; 129: 1339-1350.
4. Tohyama M, Hanakawa Y, Shirakata Y, et al,. IL-17 and IL-22 mediate IL-20 subfamily cytokine production in cultured keratinocytes via increased IL-22 receptor expression. Eur J Immunol 2009; 39: 2779-2788.
5. Toyama M, Yang L, Hanakawa Y, Dai X, Shirakata Y, Sayama K,. INF-a enhances IL-22 receptor expression in keratinocytes: a possible role in the development of psoriasis. J Invest Dermatol 2012; 132: 1933-1935.
6. Sano S, Chan KS, DiGiovanni J,. Impact of Stat3 activation upon skin biology: a dichotomy of its role between homeostasis and diseases. J Dermatol Sci 2008; 50: 1-14.
7. Liang SC, Tan XY, Luxenberg DP, et al,. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006; 203: 2271-2279.
8. Detmar M, Brown LF, Claffey KP, et al,. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 1994; 180: 1141-1146.
9. Detmar M, Brown LF, Schön MP, et al,. Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol 1998; 111: 1-6.
10. Kunstfeld R, Hirakawa S, Hong YK, et al,. VEGF-A plays a key role in the induction of chronic inflammation and the associated lymphangiogenic response. Blood 2004; 104: 1048-1057.
11. Xia YP, Li B, Hylton D, Detmar M, Yancopoulos GD, Rudge JS,. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 2003; 102: 161-168.
12. Huggenberger R, Ullmann S, Proulx ST, Pytowski B, Alitalo K, Detmar M,. Stimulation of lymphangiogenesis via VEGFR-3 inhibits chronic skin inflammation. J Exp Med 2010; 207: 2255-2269.
13. Hvid H, Teige I, Kvist PH, Svensson L, Kemp K,. TPA induction leads to a Th17-like response in transgenic K14/VEGF mice: a novel in vivo screening model of psoriasis. Int Immunol 2008; 20: 1097-1106.
14. Coimbra S, Oliveira H, Reis F, et al,. Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumour necrosis factor-a levels in patients with psoriasis before, during and after psoralen-ultraviolet A and narrowband ultraviolet B therapy. Br J Dermatol 2010; 163: 1282-1290.
15. Nakajima H, Nakajima K, Tarutani M, Morishige R, Sano S,. Kinetics of circulating Th17 cytokines and adipokines in psoriasis patients. Arch Dermatol Res 2011; 303: 451-455.
16. Lo YH, Torii K, Saito C, Furuhashi T, Maeda A, Morita A,. Serum IL-22 correlates with psoriatic severity and serum IL-6 correlates with susceptibility to phototherapy. J Dermatol Sci 2010; 58: 225-227.
17. Wolk K, Witte E, Wallace E, et al,. IL-22 regulates the expression of genes responsible for antimicrobial defence, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 2006; 36: 1309-1323.
18. Boniface K, Guignouard E, Pedretti N, et al,. A role for T cell-derived interleukin 22 in psoriatic skin inflammation. Clin Exp Immunol 2007; 150: 407-415.
19. Meephansan J, Ruchusatsawat K, Sindhupak W, Thorner PS, Wongpiyabovorn J,. Effect of methotrexate on serum levels of IL-22 in patients with psoriasis. Eur J Dermatol 2011; 21: 501-504.
20. Caproni M, Antiga E, Melani L, Volpi W, Del Bianco E, Fabbri P,. Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial. J Clin Immunol 2009; 29: 210-214.
21. Mastroianni A, Minutilli E, Mussi A, et al,. Cytokine profiles during infilixmab monotherapy in psoriasis arthritis. Br J Dermatol 2005; 153: 531-536.
22. Flisiak I, Zaniewski P, Rogalska-Taranta M, Chodynicka B,. Effect of psoriasis therapy on VEGF and its soluble receptors serum concentrations. J Eur Acad Dermatol Venereol 2012; 26: 302-307.
23. Flisiak I, Zaniewski P, Rogalska M, Mysliwiec H, Jaroszewicz J, Chondynicka B,. Effect of psoriasis activity on VEGF and its soluble receptors concentrations in serum and plaque scales. Cytokine 2010; 52: 225-229.
24. Takahashi H, Tsuji H, Hashimoto Y, Ishida-Yamamoto A, Iizuka H,. Serum cytokines and growth factor levels in Japanses patients with psoriasis. Clin Exp Dermatol 2010; 35: 645-649.
25. Zablotna M, Sobianek M, Nedoszytko B, et al,. Association of psoriasis with the VEGF gene polymorphism in the northern Polish population. J Eur Acad Dermatol Venereol 2013; 27: 319-323.
26. Nofal A, Al-Makhzangy I, Attwa E, Nassar A, Abdalmoati A,. Vascular endothelial growth factor in psoriasis: an indicator of disease severity and control. J Eur Acad Dermatol Venereol 2009; 23: 803-806.
27. Andrys C, Borska L, Pohl D, Fiala Z, Hamakova K, Krejsek J,. Angiogenic activity in patients with psoriasis is significantly decreased by Goeckerman's therapy. Arch Dermatol Res 2007; 298: 479-483.
28. Fink AM, Cauza E, Hassfeld W, et al,. Vascular endothelial growth factor in patients with psoriatic arthritis. Clin Exp Rheumatol 2007; 25: 305-308.
29. Kagami S, Rizzo HL, Lee JJ, Koguchi Y, Blauvelt A,. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol 2010; 130: 1373-1383.
30. Hino R, Kabashima R, Kawakami C, Sugita K, Nakamura M, Tokura Y,. Circulating Th17 cell fluctuation in psoriatic patients treated with topical calcipotriol and betamethasone butyrate propionate. J Eur Acad Dermatol Venereol 2011; 25: 242-244.
31. Reddy M, Torres G, McCormick T, et al,. Positive treatment effects of ustekinumab in psoriasis: analysis of lesional and systemic parameters. J Dermatol 2010; 37: 413-425.
32. Nestle FO, Conrad C, Tun-kyi A, et al,. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005; 202: 135-143.
33. Albanesi C, Scarponi C, Pallotta S, et al,. Chemerin expression marks early psoriatic skin lesions and correlates with plasmacytoid dendritic cell recruitment. J Exp Med 2009; 206: 249-258.